Overview
- Use of GLP‑1 medicines jumped after the FDA approved Wegovy for obesity in 2021, and calls to poison control about GLP‑1 exposures rose from about 100 a month in 2021 to roughly 1,000 a month by 2025.
- Patients and news reports describe severe overdoses that caused uncontrollable vomiting, dehydration, seizures, gastrointestinal bleeding, and hospital stays.
- Telehealth vendors that combine online prescribing with dispensing have shortened the path to treatment and sometimes bypassed in‑person checks and patient education about dosing and injection technique.
- The FDA says compounded GLP‑1 vials are not reviewed for safety or consistent concentration and has warned that inexperience drawing doses from vials likely contributed to dosing mistakes, prompting warning letters to telehealth firms in February.
- The surge in household GLP‑1s raises accidental pediatric exposures and other harms, which could push regulators to tighten oversight of compounding, telehealth practices, and patient counseling.